A vision for better health: mass spectrometry imaging for clinical diagnostics.
A vision for better health: mass spectrometry imaging for clinical diagnostics.
复制标题
DOI：
10.1016/j.cca.2012.10.018
复制
发表时间：
2013-05
期刊：
影响因子：
--
通讯作者：
Li L
中科院分区：
文献类型：
--
作者：
Ye H;Gemperline E;Li L
质谱成像（MSI）是一种强大的工具，通过创建选定化合物的详细分布图，赠款研究从小分子到大蛋白质的广泛分子质量范围。其在生物标志物发现中对临床应用的有用性已经通过将从MSI获得的组织的分子表达与良好建立的组织学相关联而获得成功。迄今为止，MSI已在临床应用中显示出其多功能性，例如不同疾病的生物标志物诊断、疾病严重程度的预测和药物治疗的代谢反应等。这些研究多年来为临床研究提供了重要见解，目前的技术进步正在进一步促进这一领域的改进。虽然基本的概念是简单的，因素，如电离方法的选择，样品制备，仪器和数据分析，必须考虑到成功的应用MSI。在此，我们简要回顾了这些关键要素，但集中在MSI的临床应用，不能通过其他手段解决。还讨论了该领域的挑战和未来前景，得出结论认为，随着这种强大的分析工具的不断发展，不断增长的应用将导致更好地了解疾病的生物学和临床诊断的改进。
Mass spectrometry imaging (MSI) is a powerful tool that grants the ability to investigate a broad mass range of molecules from small molecules to large proteins by creating detailed distribution maps of selected compounds. Its usefulness in biomarker discovery towards clinical applications has obtained success by correlating the molecular expression of tissues acquired from MSI with well-established histology. To date, MSI has demonstrated its versatility in clinical applications, such as biomarker diagnostics of different diseases, prognostics of disease severities and metabolic response to drug treatment, etc. These studies have provided significant insight in clinical studies over the years and current technical advances are further facilitating the improvement of this field. Although the underlying concept is simple, factors such as choice of ionization method, sample preparation, instrumentation and data analysis must be taken into account for successful applications of MSI. Herein, we briefly reviewed these key elements yet focused on the clinical applications of MSI that cannot be addressed by other means. Challenges and future perspectives in this field are also discussed to conclude that the ever-growing applications with continuous development of this powerful analytical tool will lead to a better understanding of the biology of diseases and improvements in clinical diagnostics.
登录
查看更多内容
DOI：
10.1016/j.jasms.2009.01.017
发表时间：
2009-06
影响因子：
3.2
作者：
Chen R;Hui L;Sturm RM;Li L
通讯作者：
Li L
YKL-40：一种用于临床前阿尔茨海默病的新型预后液体生物标志物。
影响因子：
10.6
作者：
Craig-Schapiro, Rebecca;Perrin, Richard J.;Roe, Catherine M.;Xiong, Chengjie;Carter, Deborah;Cairns, Nigel J.;Mintun, Mark A.;Peskind, Elaine R.;Li, Ge;Galasko, Douglas R.;Clark, Christopher M.;Quinn, Joseph F.;D'Angelo, Gina;Malone, James P.;Townsend, R. Reid;Morris, John C.;Fagan, Anne M.;Holtzman, David M.
通讯作者：
Holtzman, David M.
影响因子：
1.8
作者：
Altelaar, A. F. Maarten;Taban, Ioana M.;Piersma, Sander R.
通讯作者：
Piersma, Sander R.
影响因子：
7.4
作者：
Chaurand, P;Schwartz, SA;Caprioli, RM
通讯作者：
Caprioli, RM
影响因子：
11.5
作者：
Cazares, Lisa H.;Troyer, Dean;Semmes, O. John
通讯作者：
Semmes, O. John